Gene therapy of spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME) - Archive ouverte HAL Accéder directement au contenu
Communication Dans Un Congrès Année : 2022

Gene therapy of spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME)

Résumé

Spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME) is an autosomal recessive disorder caused by mutations in the ASAH1 gene, which codes for acid ceramidase (ACD), a lysosomal enzyme that catalyses the bioactive lipid ceramide into sphingosine and fatty acid. The disease is progressive, starting during childhood with muscle weakness and/or myoclonic seizures, and leads to death in most cases at teenage. To date, there is no curative treatment and therefore a clear unmet medical need. In the present study, we evaluated a gene therapy approach in a mouse model of acid ceramidase deficiency. We report that intravenous administration of a recombinant AAV9 vector expressing human ACD in diseased Asah1P361R/P361R mice prolonged survival of all animals until the end of a 6-month study, restored body growth and motor activity, and abolished inflammation in peripheral tissues and the central nervous system. Our findings provide proof-of-concept that systemic AAV-mediated ASAH1 gene addition can rescue the severe phenotype of a mouse model of acid ceramidase deficiency, paving the way for clinical translation in patients.
Fichier non déposé

Dates et versions

hal-04446739 , version 1 (08-02-2024)

Identifiants

  • HAL Id : hal-04446739 , version 1

Citer

Jérôme Denard, Martina Marinello, Virginie Latournerie, Delphine Bonnin, Karine Poulard, et al.. Gene therapy of spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME). SMA Europe, Oct 2022, Barcelone (Spain), Spain. ⟨hal-04446739⟩
7 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More